Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program

Students Impacted by Dermatologic Conditions Are Encouraged to Apply Through May 31, 2022

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the opening of the application process for its 2022 Aspire Higher Scholarship program. The program, which was launched in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals.

"Many students continue to balance a mix of in-person and remote education in addition to part-time jobs and extracurricular activities. We recognize how challenging it can be to manage all of these responsibilities, particularly for those who are also dealing with the physical and emotional burdens of a skin condition," said Joseph C. Papa , chairman and CEO, Bausch Health . "For nearly 10 years, we have offered the Aspire Higher Scholarship Program to help these deserving students receive the support they need to pursue their higher education, and we remain committed to doing so."

To apply for the scholarship, students are required to submit letters of recommendation along with a long-form essay describing the impact of their dermatologic condition and the role that a dermatologist, physician assistant or nurse practitioner played in helping to treat their condition. Scholarships are open to applicants who have been accepted to or students currently attending an accredited, nonprofit, two- or four-year college, university, or advanced (post-high school) vocational or technical school for the 2022-2023 academic year.

Scholarships are available in the following three categories:

  • Undergraduate Scholar Awards for students pursuing undergraduate degrees
  • Graduate Scholar Awards for students pursuing graduate degrees
  • Today's Woman Scholar Awards for students who are mothers pursuing either undergraduate or graduate degrees

"I couldn't be more grateful to have received the Ortho Dermatologics Aspire Higher Scholarship," said Olivia Kenyon , a 2021 Aspire Higher scholarship recipient and student at the University of Florida . "Thanks to the generous financial support I have been provided, I look forward to completing my undergraduate degree and attending medical school where I intend to become the first doctor in my family."

Students can apply for the Aspire Higher scholarship through May 31, 2022 . The 2022 Aspire Higher Scholarship recipients will be announced in the summer of 2022. To learn more about the scholarship, including eligibility criteria, terms and conditions and to see stories from previous winners, please visit www.AspireHigherScholarships.com .

About Aspire Higher and Other Philanthropic Initiatives
Since 2013, the Aspire Higher scholarship program has awarded 60 scholarships, providing students a total of $828,000 toward their higher education on campuses nationwide. Ortho Dermatologics also supports the Children's Skin Disease Foundation's Camp Wonder annually.

About Ortho Dermatologics
Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio also includes several leading medical device systems for aesthetic applications, such as skin tightening and resurfacing, laser hair removal and preventative therapeutic skin care treatments. More information can be found at www.ortho-dermatologics.com .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

Ortho Dermatologics is a trademark of Ortho Dermatologics' affiliated entities.
© 2022 Ortho Dermatologics' affiliated entities.
ORD.0036.USA.22

Bausch Health Investor Contact:
Arthur Shannon
arthur.shannon@bauschhealth.com
(514) 865-3855
(877) 281-6642 (toll free)

Bausch Health Media Contact:
Lainie Keller
lainie.keller@bauschhealth.com
(908) 927-1198

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/ortho-dermatologics-now-accepting-applications-for-2022-aspire-higher-scholarship-program-301493535.html

SOURCE Bausch Health Companies Inc.

News Provided by PR Newswire via QuoteMedia

BHC:CA,BHC
The Conversation (0)
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive... Keep Reading...
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigation with Norwich Pharmaceuticals, IncWith respect to the April 11, 2024, decision of the US Court of Appeals for the Federal Circuit,... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...

Latest Press Releases

Related News